There is no big difference between the price of Forxiga and DPP-4 inhibitors
On May 14, according to the related industry, AstraZeneca got healthcare insurance benefit approval of SGLT-2 inhibitor 'Forxiga (dapagliflozin)' from Health Insurance Review & Assessment, drug insurance benefit Assessment Board.
The upper price limit of Forxiga was already determined. In Last M...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
